Gilead Sciences, Inc. (GILD)

FairStock Score: 76/100 — HIGH CONVICTION

Key Financials

Strengths

• Dominant market positions in HIV and hepatitis treatments with durable competitive moats
• Exceptional free cash flow generation of $7.5B annually with 27.55% net margins
• Outstanding ROE of 40.66% demonstrates efficient capital deployment
• Strong Altman Z-Score of 3.76 indicates solid financial stability
• Diversified pipeline with T-cell therapies like Tecartus expanding beyond legacy franchises

Concerns

• Valuation is egregiously expensive at 66x EV/EBITDA with margin of safety of -444%; Graham Number suggests 80%+ overvaluation
• Absence of disclosed revenue and profit growth rates raises red flags about franchise maturity and potential stagnation
• High leverage with 1.13 D/E ratio limits financial flexibility and increases refinancing risk in rising rate environment
• FCF yield of only 1.7% provides minimal return cushion for investors at current price levels

AI Analysis

Gilead presents a mixed picture that demands careful scrutiny. On the positive side, we're looking at a pharmaceutical company with genuine competitive moats—its HIV and hepatitis treatment franchises generate substantial cash flows, evidenced by $7.5B in free cash flow and a 27.55% net margin in Q4 2025. The ROE of 40.66% is impressive, suggesting management deploys capital effectively. However, I must sound a cautionary note. The Graham Number of $26.92 versus a trading price of $146.63 represents a margin of safety of negative 444%—this is wildly overvalued by classical value metrics. The EV/EBITDA of 66x is astronomical, indicating the market prices in decades of flawless execution. The Piotroski F-Score of 7/9 is respectable but not exceptional, and that 1.13 debt-to-equity ratio bears watching. Most troubling: we cannot ascertain true earnings growth or revenue growth from the data provided, suggesting potential stagnation in core franchises. The FCF yield of 1.7% is anemic. Gilead is a quality business, yes—but at a quality price? I think not. In my experience, even excellent companies become poor investments when purchased at excessive valuations. The risk-reward is unfavorable here.

Bull Case

Gilead's HIV and hepatitis franchises remain resilient cash generators with pricing power and minimal generic competition near-term. New indications and geographic expansion, particularly in emerging markets, could reignite growth trajectories and justify premium valuations as the company pivots toward oncology and immunology.

Bear Case

Patent cliffs on core franchises combined with undisclosed revenue declines suggest mature, declining businesses trading on past glories. At 66x EV/EBITDA with thin FCF yields, even slight stumbles in pipeline execution could trigger a severe valuation reversion.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer